Citation Impact
Citing Papers
On‐treatment prediction of sustained response to peginterferon alfa‐2a for HB eAg‐negative chronic hepatitis B patients
2014
HBsAg kinetics in chronic hepatitis D during interferon therapy: on‐treatment prediction of response
2016
Gender Disparity in Liver Cancer Due to Sex Differences in MyD88-Dependent IL-6 Production
2007 StandoutScience
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial
2005 Standout
Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients
2012
A Simple Noninvasive Index Can Predict Both Significant Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C
2003 Standout
Natural history of hepatitis B
2003
Serum Hbv Dna As A Marker of Efficacy During Therapy for Chronic Hbv Infection: Analysis and Review of the Literature
2003
Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013
2015 Standout
Hepatocellular carcinoma
2018 Standout
Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog
2012
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
2007 Standout
A robust cell culture system supporting the complete life cycle of hepatitis B virus
2017 StandoutNobel
Long–Term Suppression of Hepatitis B E Antigen–Negative Chronic Hepatitis B by 24–Month Interferon Therapy
2003
Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up
2016
New insight in the pathobiology of hepatitis B virus infection
2012
Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update*
2003
Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage
2007
Hepatocellular carcinoma
2012 Standout
Hepatitis B virus infection
2009 Standout
Hepatocellular carcinoma
2021 Standout
The role of quantitative hepatitis B surface antigen revisited
2016
A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors
2019 StandoutNobel
Acute viral hepatitis increases liver stiffness values measured by transient elastography
2007
Natural history of chronic HBV infection: A cohort study with up to 12 years follow-up in North Greece (part of the Interreg I-II/EC-project)
2005
Natural History of Chronic Hepatitis B Virus Infection: What We Knew in 1981 and What We Know in 2005
2006
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
2006
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype
2013
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
2004 Standout
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women
2012
Functions of natural killer cells
2008 Standout
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Management of Hepatocellular Carcinoma *
2005 Standout
Non-alcoholic fatty liver disease
2021 Standout
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
2004 Standout
Hepatitis B Virus Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective Study in Men
2005
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
2004 Standout
Priming of hepatitis C virus-specific cytotoxic t lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA
2000 StandoutNobel
Natural history and disease progression in Chinese chronic hepatitis B patients in immune‐tolerant phase†
2007
Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level
2006 Standout
Chronic hepatitis B
2007 Standout
The natural history of chronic hepatitis B virus infection #
2009
Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US
2015
Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
2016
Chronic hepatitis B: Update 2009 #
2009 Standout
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study
2016
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
2012 Standout
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
2006
Transient Elastography for the Noninvasive Assessment of Liver Fibrosis: A Multicentre Canadian Study
2010
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
2009 StandoutNobel
Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report
2011
Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients
2002
Noninvasive assessment of liver fibrosis
2010
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
2008 Standout
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer
2017 StandoutNobel
Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease
2016
Value of Transient Elastography Measured With Fibroscan in Predicting the Outcome of Hepatic Resection for Hepatocellular Carcinoma
2012
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
2011 Standout
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B
2004
Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma
2014
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection†‡
2006 Standout
Exploring the Biological Basis of Hepatitis B E Antigen in Hepatitis B Virus Infection
2003
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Asian‐Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
2005
Antiretroviral Treatment of Adult HIV Infection
2012 Standout
Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review
2012
Hepatocellular Carcinoma
2011 Standout
Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D
2015
Performance Evaluation of New Automated Hepatitis B Viral Markers in the Clinical Laboratory
2012
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
2008 Standout
Adefovir Dipivoxil for Wait-Listed and Post–Liver Transplantation Patients with Lamivudine-Resistant Hepatitis B
2007
Hepatocellular carcinoma
2022 Standout
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B
2012
Hepatocellular Carcinoma
2019 Standout
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
2017 Standout
Chronic hepatitis B e antigen (HBeAg) negative, anti-HBe positive hepatitis B: an overview
2003
Prevention of materno‐foetal transmission of hepatitis B in sub‐Saharan Africa: the evidence, current practice and future challenges
2014
Changes of HBsAg and HBV DNA levels in C hinese chronic hepatitis B patients after 5 years of entecavir treatment
2013
Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study
2015
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems
2014 StandoutNobel
Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B
2008
Serum Levels of Hepatitis B Surface Antigen and DNA Can Predict Inactive Carriers With Low Risk of Disease Progression
2016
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment
2015
Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis
2014
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
2014 Standout
Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection
2001
Characterization of Hepatitis B Virus (HBV)-Specific T-Cell Dysfunction in Chronic HBV Infection
2007
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta‐analysis
2016
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors
2007
2013 StandoutNobel
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage
2007
Hepatitis B Virus Replication and Liver Disease Progression: The Impact of Antiviral Therapy
2006
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine
2004
Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis
2015
Nonalcoholic Fatty Liver Disease
2015 Standout
Treatment of Chronic Viral Hepatitis
2001
Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis‐4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta‐analysis
2014
HEPATIC FIBROSIS: Molecular Mechanisms and Drug Targets
2004
PD-1 and Its Ligands in Tolerance and Immunity
2008 Standout
Factors influencing liver disease progression in chronic hepatitis B
2006
Works of B. Coco being referenced
Hepatitis B Surface Antigen Serum Levels Help to Distinguish Active From Inactive Hepatitis B Virus Genotype D Carriers
2010
Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study
2002
Impact of antiviral treatment on recurrence of hepatitis B virus infection and disease
2003
Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases
2006
Liver Stiffness, a Non-Invasive Marker of Liver Disease: A Core Study Group Report
2010
Treatment of patients with chronic hepatitis C and cirrhosis
1999
Early and Accurate Prediction of Peg-IFNs/Ribavirin Therapy Outcome in the Individual Patient With Chronic Hepatitis C by Modeling the Dynamics of the Infected Cells
2008
Sustained Response to Interferon–Ribavirin Combination Therapy Predicted by a Model of Hepatitis C Virus Dynamics Using Both Hcv Rna and Alanine Aminotransferase
2003
Position paper of the Italian Association for the Study of the Liver (AISF): The multidisciplinary clinical approach to hepatocellular carcinoma
2013
Individualized Treatment of Hbeag-Negative Chronic Hepatitis B Using Pegylated Interferon-α2A as First-Line and Week-12 HBV Dna/Hbsag Stopping Rule: A Cost-Effectiveness Analysis
2013